跳至主要内容
临床试验/IRCT20130313012810N10
IRCT20130313012810N10尚未招募未知

Comparative bioequivalence study of the Apixaban 5-mg Tablets manufactured by Darman Yab Darou Company

Darman Yab Darou Pharmaceutical Company0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 60 years(—)
性别
Male

入选标准

  • The weight range of participating candidates should be between 60-100 kg
  • All candidates must be non-smokers
  • Candidates should be healthy in terms of physical examination, ECG and the following laboratory tests: Hemoglobin, Hematocrit, Red and White Blood Count, MCV (Mean Body Volume), MCH (Mean Body Hemoglobin), Routine Urinalysis, Total Cholesterol, Triglyceride, Total Proteins, albumin, uric acid, total bilirubin, alkaline phosphatase, gamma glutamyl transpeptidase (?-GT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea, creatinine and fasting blood glucose
  • Volunteers who have agreed to an informed consent form
  • All candidates should not consume caffeine-containing drinks and chocolate during two days before the prescription, and this restriction must be followed until the last blood draw

排除标准

  • History of allergic or adverse reaction to Esomeprazole or any similar product
  • Volunteers with blood pressure less than 60/90 mm Hg or higher than 90/140 mm Hg
  • Individuals who donated whole blood or blood components within 2 months within 2 weeks prior to the first dose of the study product(s)

研究者

发起方
Darman Yab Darou Pharmaceutical Company

相似试验